Teva Pharmaceutical Industries Limited American Depositary Shares (TEVA): Price and Financial Metrics
Teva Pharmaceutical Industries Limited American Depositary Shares (TEVA)
Today's Latest Price: $8.34 USD
Updated Apr 3 1:05pm
Add TEVA to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 214 in Medical - Pharmaceuticals
See all "A" rated Strong Buy stocks
TEVA Stock Summary
- With a market capitalization of $8,868,574,737, Teva Pharmaceutical Industries Ltd has a greater market value than 87.25% of US stocks.
- Revenue growth over the past 12 months for Teva Pharmaceutical Industries Ltd comes in at -10.43%, a number that bests only 15.93% of the US stocks we're tracking.
- Teva Pharmaceutical Industries Ltd's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is 21.01%, greater than the shareholder yield of 83.84% of stocks in our set.
- If you're looking for stocks that are quantitatively similar to Teva Pharmaceutical Industries Ltd, a group of peers worth examining would be HAS, BC, GRA, TRIB, and TG.
- TEVA's SEC filings can be seen here. And to visit Teva Pharmaceutical Industries Ltd's official web site, go to www.tevapharm.com.
TEVA Stock Price Chart More Charts
TEVA Price/Volume Stats
| Current price | $8.34 | 52-week high | $15.72 |
| Prev. close | $8.12 | 52-week low | $6.07 |
| Day low | $8.10 | Volume | 9,083,179 |
| Day high | $8.62 | Avg. volume | 22,126,248 |
| 50-day MA | $10.30 | Dividend yield | N/A |
| 200-day MA | $8.91 | Market Cap | 9.11B |
Teva Pharmaceutical Industries Limited American Depositary Shares (TEVA) Company Bio
Teva Pharmaceuticals manufactures, markets, and distributes generic, specialty, and other pharmaceutical products worldwide. The company operates in two segments, Generic Medicines and Specialty Medicines. The company was founded in 1901 and is based in Petach Tikva, Israel.
TEVA Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $8.34 | $0.03 | -100% |
We started the process of determining a valid price forecast for Teva Pharmaceutical Industries Ltd with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Teva Pharmaceutical Industries Ltd ranked in the 0th percentile in terms of potential gain offered. Our DCF analysis suggests the stock is overvalued by about 100%. The most interesting components of our discounted cash flow analysis for Teva Pharmaceutical Industries Ltd ended up being:
- In the past 5.04 years, Teva Pharmaceutical Industries Ltd has a compound free cash flow growth rate of -0.44%; that's better than just 4.98% of cash flow producing equities in the Healthcare sector, where it is classified.
- 24% of the company's capital comes from equity, which is greater than only 14.78% of stocks in our cash flow based forecasting set.
- Teva Pharmaceutical Industries Ltd's interest coverage rate -- a measure of gross earnings relative to interest payments -- comes in at -0.55. This coverage rate is greater than that of merely 15.54% of stocks we're observing for the purpose of forecasting via discounted cash flows.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | -100% |
| 1% | -100% |
| 2% | -100% |
| 3% | -100% |
| 4% | -100% |
| 5% | -100% |
For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as TEVA, try AGHC, ALC, AMPH, CSII, and ELAN.
Loading social stream, please wait...